Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Hervé Ghesquières, Guillaume Cartron, John Francis Seymour, Marie-Hélène Delfau-Larue, Fritz Offner, Pierre Soubeyran, Aurore Perrot, Pauline Brice, Réda Bouabdallah, Anne Sonet, Jehan Dupuis, Olivier Casasnovas, John Vincent Catalano, Alain Delmer, Fabrice Jardin, Aurélie Verney, Peggy Dartigues, Gilles Salles, Hervé Ghesquières, Guillaume Cartron, John Francis Seymour, Marie-Hélène Delfau-Larue, Fritz Offner, Pierre Soubeyran, Aurore Perrot, Pauline Brice, Réda Bouabdallah, Anne Sonet, Jehan Dupuis, Olivier Casasnovas, John Vincent Catalano, Alain Delmer, Fabrice Jardin, Aurélie Verney, Peggy Dartigues, Gilles Salles
Abstract
In patients with follicular lymphoma treated with single-agent rituximab, single nucleotide polymorphisms in the FCGR3A gene are known to influence response and progression-free survival. The prognostic role of FCGR3A and FCGR2A polymorphisms in patients with follicular lymphoma treated with rituximab and chemotherapy combination remains controversial and has not been evaluated in the context of rituximab maintenance. FCGR3A and FCGR2A single nucleotide polymorphisms were evaluated in, respectively, 460 and 455 patients treated in the PRIMA study to investigate whether these were associated with response rate and patient outcome after rituximab chemotherapy induction and 2-year rituximab maintenance. In this representative patient cohort, complete and unconfirmed complete responses after rituximab chemotherapy were observed in 65%, 67%, 66% (P = .86) and 60%, 72%, 66% (P = .21) of FCGR3A VV, VF, FF and FCGR2A HH, HR, RR carriers, respectively. After 2 years of rituximab maintenance (or observation), response rates did not differ among the different genotypes. Progression-free survival measured from either treatment initiation or randomization to observation or maintenance was not influenced by these polymorphisms. These data indicate that FCGR3A and FCGR2A polymorphisms do not influence response rate and outcome when rituximab is combined with chemotherapy or used as maintenance treatment. The PRIMA study is registered at www.clinicaltrials.gov as NCT00140582.
Source: PubMed